Stryker Corporation (SYK) Receives Average Recommendation of “Hold” from Analysts
Shares of Stryker Corporation (NYSE:SYK) have received a consensus recommendation of “Hold” from the twenty-five research firms that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation and thirteen have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $152.94.
Several brokerages have recently issued reports on SYK. Cantor Fitzgerald restated a “neutral” rating on shares of Stryker in a research report on Friday. Royal Bank of Canada restated a “buy” rating and issued a $155.00 price objective on shares of Stryker in a research report on Monday, October 2nd. SunTrust Banks restated a “buy” rating and issued a $161.00 price objective on shares of Stryker in a research report on Monday, October 2nd. Wells Fargo & Co restated an “outperform” rating and issued a $174.00 price objective (up from $166.00) on shares of Stryker in a research report on Tuesday. They noted that the move was a valuation call. Finally, Oppenheimer set a $156.00 price objective on Stryker and gave the company a “hold” rating in a research report on Monday, October 30th.
In related news, insider Lonny J. Carpenter sold 5,000 shares of the stock in a transaction dated Friday, November 3rd. The stock was sold at an average price of $155.34, for a total transaction of $776,700.00. Following the transaction, the insider now directly owns 83,207 shares in the company, valued at $12,925,375.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 7.40% of the company’s stock.
Stryker (NYSE:SYK) traded down $0.05 during trading on Friday, reaching $158.74. The company’s stock had a trading volume of 862,400 shares, compared to its average volume of 1,107,267. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.37 and a quick ratio of 1.61. The firm has a market capitalization of $60,200.00, a price-to-earnings ratio of 33.85, a price-to-earnings-growth ratio of 2.27 and a beta of 0.78. Stryker has a 12 month low of $116.50 and a 12 month high of $160.62.
Stryker (NYSE:SYK) last posted its earnings results on Thursday, October 26th. The medical technology company reported $1.52 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.50 by $0.02. Stryker had a return on equity of 24.11% and a net margin of 14.67%. The company had revenue of $3.01 billion for the quarter, compared to analyst estimates of $2.97 billion. During the same quarter in the prior year, the company earned $1.39 earnings per share. Stryker’s revenue was up 6.1% compared to the same quarter last year. equities research analysts anticipate that Stryker will post 6.47 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 31st. Investors of record on Friday, December 29th will be given a dividend of $0.47 per share. The ex-dividend date is Thursday, December 28th. This is an increase from Stryker’s previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a yield of 1.18%. Stryker’s dividend payout ratio is 40.09%.
ILLEGAL ACTIVITY WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/05/stryker-corporation-syk-receives-average-recommendation-of-hold-from-analysts.html.
Stryker Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.